Grow Everything Biotech Podcast · Alternative Proteins · November 2026
The hosts were discussing Anthropic's acquisition of a one-person AI-driven drug company. Karl argues that AI tools turn the one-person biotech into a repeatable model.
…going for rare muscular dystrophies. What motivated him to go into that? Because it's just one of those things that it's rare. Like those are rare diseases. And to be so focused on that, and apparently he coordinated 11 external laboratories and part-time consultants. I mean, it's just amazing.
…if you are a biotech founder listening to this, this is a case study you really need to spend time digging into and seeing how it all came together. I mean, I'm sure there's lots of decision points that aren't shared publicly, but you're going to have to do the mental gymnastics to figure it out.
Yeah, I mean, it's no longer the two-person biotech company. It's now the one-person biotech and the one-person virtual biotech company. So imagine what someone in Guatemala could do with these tools to solve a disease that is local. I think that this is super exciting. And there's a venture capitalist whose name I forget, who I follow on Instagram. And he's like, we're going to see every deck that involves someone looking for funding for drugs is going to mention how they're using these tools and are accelerating what they're doing. And I see it.
Yeah, I see it with the class I'm involved with. These students, we're getting very far in terms of developing products, but that's just, again, the technology is one aspect of it. You have to be able to go out into the world, talk to the people that need to help you build the product, and then to…
Okay. So Iram, you started off by saying what the actual F is going on. Did you see this Warhound news?
Oh my God. Oh my God. I don't even know what to say. It's actually really funny. No, not the story, which we're going to talk about, the Warhound, but I had someone text me and they're like, did you hear this news about Colossal? And they texted me right after we talked about the bird, that…